{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:19:37Z","timestamp":1788401977375,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01073-0","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:55:31Z","timestamp":1774022131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experimental evaluation of N-acetylcysteine against doxorubicin cardiotoxicity in rats"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5250-3748","authenticated-orcid":false,"given":"Hasan Tahsin","family":"Tola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-5538","authenticated-orcid":false,"given":"Sinan","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"1073_CR1","doi-asserted-by":"publisher","first-page":"119527","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527. https:\/\/doi.org\/10.1016\/j.lfs.2021.119527.","journal-title":"Life Sci"},{"issue":"4","key":"1073_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, et al. Doxorubicin-Induced cardiotoxicity: an overview on Pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292\u2013310. https:\/\/doi.org\/10.1007\/s12012-022-09721-1.","journal-title":"Cardiovasc Toxicol"},{"key":"1073_CR3","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1073_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","volume":"18","author":"CY Kong","year":"2022","unstructured":"Kong CY, Guo Z, Song P, et al. Underlying the mechanisms of Doxorubicin-Induced acute cardiotoxicity: oxidative stress and cell death. Int J Biol Sci. 2022;18(2):760\u201370. https:\/\/doi.org\/10.7150\/ijbs.65258. Published 2022 Jan 1.","journal-title":"Int J Biol Sci"},{"issue":"13","key":"1073_CR5","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale R, Marzocco S, Popolo A. Role of oxidative stress and inflammation in Doxorubicin-Induced cardiotoxicity: A brief account. Int J Mol Sci. 2024;25(13):7477. https:\/\/doi.org\/10.3390\/ijms25137477. Published 2024 Jul 8.","journal-title":"Int J Mol Sci"},{"key":"1073_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat A, Kleinerman ES. Anthracycline-Induced cardiotoxicity: Causes, Mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181\u201392. https:\/\/doi.org\/10.1007\/978-3-030-43032-0_15.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1073_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccl.2024.08.002","volume":"43","author":"E Balough","year":"2025","unstructured":"Balough E, Ariza A, Asnani A, Hoeger CW. Cardiotoxicity of anthracyclines. Cardiol Clin. 2025;43(1):111\u201327. https:\/\/doi.org\/10.1016\/j.ccl.2024.08.002.","journal-title":"Cardiol Clin"},{"issue":"3","key":"1073_CR8","first-page":"265","volume":"80","author":"PJ Millea","year":"2009","unstructured":"Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265\u20139.","journal-title":"Am Fam Physician"},{"issue":"8","key":"1073_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1570159X19666201230144109","volume":"19","author":"G Raghu","year":"2021","unstructured":"Raghu G, Berk M, Campochiaro PA, et al. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021;19(8):1202\u201324. https:\/\/doi.org\/10.2174\/1570159X19666201230144109.","journal-title":"Curr Neuropharmacol"},{"key":"1073_CR10","doi-asserted-by":"publisher","first-page":"105354","DOI":"10.1016\/j.tiv.2022.105354","volume":"81","author":"W Wang","year":"2022","unstructured":"Wang W, Chen E, Ding X, et al. N-acetylcysteine protect inner hair cells from cisplatin by alleviated celluar oxidative stress and apoptosis. Toxicol Vitro. 2022;81:105354. https:\/\/doi.org\/10.1016\/j.tiv.2022.105354.","journal-title":"Toxicol Vitro"},{"issue":"6","key":"1073_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0960327112467043","volume":"32","author":"V Arica","year":"2013","unstructured":"Arica V, Demir \u0130H, Tutanc M, et al. N-acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats. Hum Exp Toxicol. 2013;32(6):655\u201361. https:\/\/doi.org\/10.1177\/0960327112467043.","journal-title":"Hum Exp Toxicol"},{"issue":"4","key":"1073_CR12","first-page":"20","volume":"46","author":"R Hayward","year":"2007","unstructured":"Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007;46(4):20\u201332.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"1073_CR13","doi-asserted-by":"publisher","unstructured":"Meng C, Fan L, Wang X, et al. Preparation and evaluation of animal models of cardiotoxicity in antineoplastic therapy. Oxid Med Cell Longev. 2022;2022:3820591. https:\/\/doi.org\/10.1155\/2022\/3820591","DOI":"10.1155\/2022\/3820591"},{"issue":"18","key":"1073_CR14","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.2174\/1871520621666201229115612","volume":"21","author":"L Zhu","year":"2021","unstructured":"Zhu L, Lin M. The synthesis of Nano-Doxorubicin and its anticancer effect. Anticancer Agents Med Chem. 2021;21(18):2466\u201377. https:\/\/doi.org\/10.2174\/1871520621666201229115612.","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"1073_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. https:\/\/doi.org\/10.1038\/s41419-021-03614-x. Published 2021 Apr 1.","journal-title":"Cell Death Dis"},{"key":"1073_CR16","doi-asserted-by":"publisher","unstructured":"Li Y, Yan J, Yang P. The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: role of programmed cell death. Cell Stress Chaperones. 2024;29(5):666\u2013680. https:\/\/doi.org\/10.1016\/j.cstres.2024.10.005.]. Cell Stress Chaperones. 2024;29(5):666\u2013680. doi:10.1016\/j.cstres.2024.09.001.","DOI":"10.1016\/j.cstres.2024.10"},{"key":"1073_CR17","doi-asserted-by":"publisher","first-page":"101747","DOI":"10.1016\/j.redox.2020.101747","volume":"37","author":"C Hu","year":"2020","unstructured":"Hu C, Zhang X, Song P, et al. Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP\/PKA\/SIRT1 pathway. Redox Biol. 2020;37:101747. https:\/\/doi.org\/10.1016\/j.redox.2020.101747.","journal-title":"Redox Biol"},{"issue":"2","key":"1073_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12012-007-0018-0","volume":"7","author":"A Bast","year":"2007","unstructured":"Bast A, Haenen GR, Bruynzeel AM, Van der Vijgh WJ. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol. 2007;7(2):154\u20139. https:\/\/doi.org\/10.1007\/s12012-007-0018-0.","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"1073_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10565-006-0142-9","volume":"23","author":"J Robert","year":"2007","unstructured":"Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2007;23(1):27\u201337. https:\/\/doi.org\/10.1007\/s10565-006-0142-9.","journal-title":"Cell Biol Toxicol"},{"issue":"11","key":"1073_CR20","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1161\/CIRCRESAHA.122.321587","volume":"132","author":"W Luo","year":"2023","unstructured":"Luo W, Zou X, Wang Y, et al. Critical role of the cGAS-STING pathway in Doxorubicin-Induced cardiotoxicity. Circ Res. 2023;132(11):e223\u201342. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321587.","journal-title":"Circ Res"},{"key":"1073_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2147\/IJN.S296272","volume":"16","author":"E Gallo","year":"2021","unstructured":"Gallo E, Diaferia C, Rosa E, Smaldone G, Morelli G, Accardo A. Peptide-Based hydrogels and nanogels for delivery of doxorubicin. Int J Nanomed. 2021;16:1617\u201330. https:\/\/doi.org\/10.2147\/IJN.S296272. Published 2021 Mar 1.","journal-title":"Int J Nanomed"},{"issue":"3","key":"1073_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s0008-6363(98)00034-0","volume":"38","author":"P Venditti","year":"1998","unstructured":"Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res. 1998;38(3):695\u2013702. https:\/\/doi.org\/10.1016\/s0008-6363(98)00034-0.","journal-title":"Cardiovasc Res"},{"key":"1073_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"307","author":"M Songbo","year":"2019","unstructured":"Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41\u20138. https:\/\/doi.org\/10.1016\/j.toxlet.2019.02.013.","journal-title":"Toxicol Lett"},{"issue":"4","key":"1073_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.biochi.2011.02.015","volume":"94","author":"S Ghibu","year":"2012","unstructured":"Ghibu S, Delemasure S, Richard C, et al. General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid. Biochimie. 2012;94(4):932\u20139. https:\/\/doi.org\/10.1016\/j.biochi.2011.02.015.","journal-title":"Biochimie"},{"issue":"1\u20132","key":"1073_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/A:1006962027887","volume":"196","author":"N Iliskovic","year":"1999","unstructured":"Iliskovic N, Hasinoff BB, Malisza KL, Li T, Danelisen I, Singal PK. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem. 1999;196(1\u20132):43\u20139.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"1073_CR26","first-page":"727","volume":"150","author":"N Iliskovic","year":"1997","unstructured":"Iliskovic N, Singal PK. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol. 1997;150(2):727\u201334.","journal-title":"Am J Pathol"},{"issue":"9\u201310","key":"1073_CR27","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/s0891-5849(98)00303-7","volume":"26","author":"X Luo","year":"1999","unstructured":"Luo X, Reichetzer B, Trines J, Benson LN, Lehotay DC. L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats. Free Radic Biol Med. 1999;26(9\u201310):1158\u201365. https:\/\/doi.org\/10.1016\/s0891-5849(98)00303-7.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"1073_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4142\/jvs.2003.4.2.129","volume":"4","author":"ES Park","year":"2003","unstructured":"Park ES, Kim SD, Lee MH, et al. Protective effects of N-acetylcysteine and selenium against doxorubicin toxicity in rats. J Vet Sci. 2003;4(2):129\u201336.","journal-title":"J Vet Sci"},{"issue":"3","key":"1073_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/phrs.2000.0769","volume":"43","author":"SY Saad","year":"2001","unstructured":"Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001;43(3):211\u20138. https:\/\/doi.org\/10.1006\/phrs.2000.0769.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1073_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11418-012-0683-6","volume":"67","author":"C Chaotham","year":"2013","unstructured":"Chaotham C, De-Eknamkul W, Chanvorachote P. Protective effect of Plaunotol against doxorubicin-induced renal cell death. J Nat Med. 2013;67(2):311\u20139. https:\/\/doi.org\/10.1007\/s11418-012-0683-6.","journal-title":"J Nat Med"},{"key":"1073_CR31","doi-asserted-by":"crossref","unstructured":"Tadokoro T, Ikeda M, Ide T et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity [published correction appears in JCI Insight. 2023;8(6):e169756. JCI Insight. 2020;5(9):e132747. Published 2020 May 7. https:\/\/doi.org\/10.1172\/jci.insight.132747","DOI":"10.1172\/jci.insight.132747"},{"issue":"4","key":"1073_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1172\/jci110328","volume":"68","author":"JH Doroshow","year":"1981","unstructured":"Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981;68(4):1053\u201364. https:\/\/doi.org\/10.1172\/jci110328.","journal-title":"J Clin Invest"},{"key":"1073_CR33","doi-asserted-by":"publisher","first-page":"113903","DOI":"10.1016\/j.biopha.2022.113903","volume":"156","author":"Y Chen","year":"2022","unstructured":"Chen Y, Shi S, Dai Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed Pharmacother. 2022;156:113903. https:\/\/doi.org\/10.1016\/j.biopha.2022.113903.","journal-title":"Biomed Pharmacother"},{"key":"1073_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.phymed.2018.01.009","volume":"40","author":"J Yu","year":"2018","unstructured":"Yu J, Wang C, Kong Q, Wu X, Lu JJ, Chen X. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine. 2018;40:125\u201339. https:\/\/doi.org\/10.1016\/j.phymed.2018.01.009.","journal-title":"Phytomedicine"},{"issue":"11","key":"1073_CR35","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/ijms18112490","volume":"18","author":"M Lewandowski","year":"2017","unstructured":"Lewandowski M, Gwozdzinski K. Nitroxides as antioxidants and anticancer drugs. Int J Mol Sci. 2017;18(11):2490. https:\/\/doi.org\/10.3390\/ijms18112490. Published 2017 Nov 22.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1073_CR36","doi-asserted-by":"publisher","first-page":"e44990","DOI":"10.1371\/journal.pone.0044990","volume":"7","author":"EJ Park","year":"2012","unstructured":"Park EJ, Kwon HK, Choi YM, Shin HJ, Choi S. Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3. PLoS ONE. 2012;7(9):e44990. https:\/\/doi.org\/10.1371\/journal.pone.0044990.","journal-title":"PLoS ONE"},{"issue":"8","key":"1073_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","volume":"18","author":"M St\u011brba","year":"2013","unstructured":"St\u011brba M, Popelov\u00e1 O, V\u00e1vrov\u00e1 A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and Pharmacological cardioprotection. Antioxid Redox Signal. 2013;18(8):899\u2013929. https:\/\/doi.org\/10.1089\/ars.2012.4795.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1073_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s1734-1140(09)70018-0","volume":"61","author":"T Sim\u016fnek","year":"2009","unstructured":"Sim\u016fnek T, St\u00e9rba M, Popelov\u00e1 O, Adamcov\u00e1 M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154\u201371. https:\/\/doi.org\/10.1016\/s1734-1140(09)70018-0.","journal-title":"Pharmacol Rep"},{"issue":"4","key":"1073_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s1043-6618(03)00185-3","volume":"48","author":"M Yagmurca","year":"2003","unstructured":"Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak MK. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res. 2003;48(4):377\u201382. https:\/\/doi.org\/10.1016\/s1043-6618(03)00185-3.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1073_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/0974-8490.85012","volume":"3","author":"SS Shiromwar","year":"2011","unstructured":"Shiromwar SS, Chidrawar VR. Combined effects of p-coumaric acid and naringenin against doxorubicin-induced cardiotoxicity in rats. Pharmacognosy Res. 2011;3(3):214\u20139. https:\/\/doi.org\/10.4103\/0974-8490.85012.","journal-title":"Pharmacognosy Res"},{"issue":"3","key":"1073_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cphy.c180017","volume":"9","author":"TR Mancilla","year":"2019","unstructured":"Mancilla TR, Iskra B, Aune GJ. Doxorubicin-Induced cardiomyopathy in children. Compr Physiol. 2019;9(3):905\u201331. https:\/\/doi.org\/10.1002\/cphy.c180017. Published 2019 Jun 12.","journal-title":"Compr Physiol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01073-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01073-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01073-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:15:21Z","timestamp":1777425321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01073-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01073-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was granted by the Ethics Committee of the Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey (Decision No: 11, Date: 20 February 2008). The experimental study was initiated immediately after approval. All procedures were conducted in accordance with institutional and national guidelines for the care and use of laboratory animals, consistent with the European Directive 2010\/63\/EU. All data reported in this manuscript are original and have not been previously published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}